Following a re-submission
rufinamide (Inovelon®) is accepted for restricted use within NHS Scotland as adjunctive therapy in the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients four years and older.
Adjunctive rufinamide significantly reduced the frequency of total seizures and tonic-atonic seizures and significantly improved seizure severity when compared to placebo in patients with LGS. Rufinamide is restricted to use in patients who have failed treatment with or are intolerant of alternative traditional antiepileptic drugs.
Download detailed advice125KB (PDF)
- Medicine name:
- rufinamide 100mg, 200mg, 400mg tablets (Inovelon)
- SMC ID:
- Seizures assocaited with Lennox-Gastaut syndrome in patients four years and older
- Pharmaceutical company
- Eisai Ltd
- BNF chapter
- Central nervous system
- Submission type
- Date advice published
- 10 November 2008